Issue

Vol. 35 No. 4 (2023): Vol 35 Issue 4, 2023

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Nitrosamine Impurities: Assessing Concerns through Case Studies: A Review

https://doi.org/10.14233/ajchem.2023.27603
Monalisha Jena
Bharati Vidyapeeth’s College of Pharmacy (Affiliated to University of Mumbai), Sector-8, CBD Belapur, Navi Mumbai-400614, India
Misbah Mukadam
Bharati Vidyapeeth’s College of Pharmacy (Affiliated to University of Mumbai), Sector-8, CBD Belapur, Navi Mumbai-400614, India
Divya Telange
Bharati Vidyapeeth’s College of Pharmacy (Affiliated to University of Mumbai), Sector-8, CBD Belapur, Navi Mumbai-400614, India
Ruchika Dolas
Bharati Vidyapeeth’s College of Pharmacy (Affiliated to University of Mumbai), Sector-8, CBD Belapur, Navi Mumbai-400614, India
C.S. Ramaa
Bharati Vidyapeeth’s College of Pharmacy (Affiliated to University of Mumbai), Sector-8, CBD Belapur, Navi Mumbai-400614, India
https://orcid.org/0000-0002-5814-3616

Corresponding Author(s) : C.S. Ramaa

ramaa.cs@bvcop.in

Asian Journal of Chemistry, Vol. 35 No. 4 (2023): Vol 35 Issue 4, 2023

Abstract

N-nitrosamines are potential human carcinogens that can be ingested from a range of known sources, including food, drinking water, tobacco smoke and cosmetic goods. Remarkably, their prevalence in medicinal products went undetected until mid-2018. These contaminants were first detected in the active pharmaceutical ingredient (API) of valsartan and other sartan medicines were eventually implicated. The regulatory response to the nitrosamines issue included a recommendation to all marketing authorization holders (MAHs) for human medicinal products containing chemically synthesized active pharmaceutical ingredients to evaluate the potential hazards of nitrosamines in their products and implement appropriate risk mitigation checks and balances. The objective of this review is to investigate various realms associated with investigating how these genotoxic and carcinogenic impurities may be formed during the manufacture or preservation/storage of a wide range of drugs, including sartans (losartan, valsartan), anti-diabetics (metformin, pioglitazone) and a few antacids (ranitidine) and a thorough literature review on case-studies, drug-excipient interactions, metabolic activation and other prospects.

Keywords

Nitrosamines Carcinogenicity Nitrosation Nitrosamine impurities
Jena, M., Mukadam, M., Telange, D., Dolas, R., & Ramaa, C. (2023). Nitrosamine Impurities: Assessing Concerns through Case Studies: A Review. Asian Journal of Chemistry, 35(4), 794–804. https://doi.org/10.14233/ajchem.2023.27603
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Food and Drug Administration, Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry (Rev. 1), September, p. 24 (2021); https://www.fda.gov/media/141720/download
  2. International Agency for Research on Cancer, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, vol. 1-42, IARC; Lyon, France (1987).
  3. J.C. Beard and T.M. Swager, J. Org. Chem., 86, 2037 (2021); https://doi.org/10.1021/acs.joc.0c02774
  4. R. Boetzel, J. Schlingemann, S. Hickert, C. Korn, G. Kocks, B. Luck, G. Blom, M. Harrison, M. François, L. Allain, Y. Wu and Y. Bousraf, J. Pharm. Sci., (2022); https://doi.org/10.1016/j.xphs.2022.04.016
  5. European Medicines Agency, Assessment Report: Nitrosamine Impurities in Human Medicinal Products, EMA/369136/2020, vol. 5, no. June, pp. 1-90 (2020); https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf
  6. Y. Wu, J. Levons, A.S. Narang, K. Raghavan and V.M. Rao, AAPS PharmSciTech, 12, 1248 (2011); https://doi.org/10.1208/s12249-011-9677-z
  7. G.W. Sluggett, T. Zelesky, E.M. Hetrick, Y. Babayan and S.W. Baertschi, J. Pharm. Biomed. Anal., 149, 206 (2018); https://doi.org/10.1016/j.jpba.2017.10.035
  8. M.J. Giridharan and R. Srinivasan, Ann. Roman. Soc. Cell Biol., 25, 1633 (2021).
  9. M.K. Parr and J.F. Joseph, J. Pharm. Biomed. Anal., 164, 536 (2019); https://doi.org/10.1016/j.jpba.2018.11.010
  10. R. Zou, X. Liao, L. Zhao and B. Yuan, Environ. Sci. Pollut. Res., 25, 13489 (2018); https://doi.org/10.1007/s11356-018-1470-z
  11. J.L. Roux, J. Croue, M. Deborde, S. Papot and M. Deborde, Environ. Sci. Technol., 46, 11095 (2012); https://doi.org/10.1021/es3023094
  12. M. Hazarika, Nitrosamine-A Big No for Printing Inks for Food and Pharma Packaging, The Packman Mag., February 16 (2020); https://thepackman.in/nitrosamine-a-big-no-for-printing-inks-for-food-and-pharma-packaging/
  13. European Medicines Agency, Information on Nitrosamines for Marketing Authorisation Holders, Ema/189634/2019, vol. 5, pp. 1-5 (2019); https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-information-nitrosamines-marketing-authorisation-holders-obsolete_.pdf
  14. J.P. Dattatraya, S.N. Arun, V.K. Deshmukh, V. B. Ghawate and A.R. Pund, Pharm. Resonance, 4, 44 (2022).
  15. C. Adoption and C. Date, ICH Guideline M7 (R1) on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, vol. 7, no. 2 (2018).
  16. K. Li, K. Ricker, F.C. Tsai, C.Y.J. Hsieh, G. Osborne, M. Sun, M.E. Marder, S. Elmore, R. Schmitz and M.S. Sandy, Int. J. Environ. Res. Public Health, 18, 9465 (2021); https://doi.org/10.3390/ijerph18189465
  17. J. Schlingemann, M.J. Burns, D.J. Ponting, C.M. Avila, N.E. Romero, M.A. Jaywant, G.F. Smith, I.W. Ashworth, S. Simon, C. Saal and A. Wilk, J. Pharm. Sci., (2022); https://doi.org/10.1016/j.xphs.2022.11.013.2022
  18. European Medicines Regulatory Network Approach for the Implemen-tation of the CHMP Opinion Pursuant to Article 5(3) of Regulation (EC) No. 726/2004 for Nitrosamine Impurities in Human Medicines, vol. 5, no. 726 (2021).
  19. J.M. Kemper, S.S. Walse and W.A. Mitch, Environ. Sci. Technol., 44, 1224 (2010); https://doi.org/10.1021/es902840h
  20. D.J. Snodin, Org. Process Res. Dev., 24, 2407 (2020); https://doi.org/10.1021/acs.oprd.0c00343
  21. R. Thomas, R.E. Tennant, A.A.F. Oliveira and D.J. Ponting, Chem. Res. Toxicol., 35, 1997 (2022); https://doi.org/10.1021/acs.chemrestox.2c00199
  22. R. Thomas, R. Ponting and R. Thresher, Regul. Toxicol. Pharmacol., 121, 104875 (2021); https://doi.org/10.1016/j.yrtph.2021.104875
  23. USFDA, No Title; https://www.fda.gov/drugs/news-events-human-drugs/nitrosamines-impurities-drugs-health-risk-assessment-and-mitigation-public-workshop-03292021
  24. R.P. Hanzlik and K.H.J. Ling, J. Org. Chem., 55, 3992 (1990); https://doi.org/10.1021/jo00300a010
  25. D.A. Smith, L. Di and E.H. Kerns, Nat. Rev. Drug Discov., 9, 929 (2010); https://doi.org/10.1038/nrd3287
  26. Z. Zhivkova and I. Doytchinova, J. Pharm. Sci., 101, 4627 (2012); https://doi.org/10.1002/jps.23303
  27. P. Gardiner, R.J. Cox and K. Grime, Drug Metab. Dispos., 47, 865 (2019); https://doi.org/10.1124/dmd.119.087163
  28. R. Lonsdale, K.T. Houghton, J. Zurek, C.M. Bathelt, N. Foloppe, M.J. De Groot, J.N. Harvey and A.J. Mulholland, J. Am. Chem. Soc., 135, 8001 (2013); https://doi.org/10.1021/ja402016p
  29. D.F. Lewis and Y. Ito, Expert Opin. Drug Metab. Toxicol., 6, 661 (2010); https://doi.org/10.1517/17425251003674380
  30. N.R. Loeppky, Nitrosamine and N-Nitroso Compound Chemistry and Biochemistry, Advances and Perspectives; ACS Symposium Series, vol. 553, Chap. 1, pp. 1-8 (1994).
  31. B. Jose, E.J. Jesy and R.J. Nedumpara, World J. Pharm. Res., 3, 5041 (2014); https://doi.org/10.20959/wjpr202111-21490
  32. P.V. Ajith Kumar and M. Deepa, Int. J. Res. Med. Sci., 8, 3778 (2020); https://doi.org/10.18203/2320-6012.ijrms20204273
  33. B. Tuesuwan and V. Vongsutilers, J. Pharm. Sci., 110, 3118 (2021); https://doi.org/10.1016/j.xphs.2021.04.021
  34. D.A. Keire, R. Bream, U. Wollein, J. Schmaler-Ripcke, A. Burchardt, M. Conti, A. Zmyslowski, P. Keizers, J. Morin, J. Poh, M. George and M. Wierer, AAPS J., 24, 56 (2022); https://doi.org/10.1208/s12248-022-00702-4
  35. S.C. Jagdale, S.A. Patil, B.S. Kuchekar and A.R. Chabukswar, J. Young Pharm., 3, 197 (2011); https://doi.org/10.4103/0975-1483.83758
  36. H. Yokoo, E. Yamamoto, S. Masada, N. Uchiyama, T. Hakamatsuka, G. Tsuji, Y. Demizu, K. Izutsu and Y. Goda, Chem. Pharm. Bull. (Tokyo), 69, 872 (2021); https://doi.org/10.1248/cpb.c21-00289
  37. S.M. De La Monte and M. Tong, J. Alzheimers Dis., 17, 817 (2009); https://doi.org/10.3233/JAD-2009-1098
  38. S. Schmidtsdorff, J. Neumann, A.H. Schmidt and M.K. Parr, Arch. Pharm., 356, 2200484 (2023); https://doi.org/10.1002/ardp.202200484
  39. G. Eisenbrand, B. Spiegelhalder, J. Kann, R. Klein and R. Preussmann, Arzneimittelforschung, 29, 867 (1979); https://doi.org/10.1002/chin.197938327
  40. J. Reisch, H. Alfes, N. Jantos and H. Möllmann, Acta Pharm Suec., 5, 393 (1968).
  41. J. Reisch, R. Pagnucco, H. Alfes, N. Jantos and H. Möllmann, J. Pharm. Pharmacol., 20, 81 (1968); https://doi.org/10.1111/j.2042-7158.1968.tb09693.x
  42. I. Sedlo, T. Kolonic and S. Tomic, Arh. Hig. Rada Toksikol., 72, 1 (2021); https://doi.org/10.2478/aiht-2021-72-3491
  43. Y.D. Liu, M. Selbes, C. Zeng, R. Zhong and T. Karanfil, Environ. Sci. Technol., 48, 8653 (2014); https://doi.org/10.1021/es500997e
  44. M. Adachi, H. Saito, H. Kobayashi, Y. Horie, S. Kato, M. Yoshioka and H. Ishii, Ann. Intern. Med., 139, 488 (2003); https://doi.org/10.7326/0003-4819-139-6-200309160-00012
  45. D. Gonzales, S.I. Rennard, M. Nides, C. Oncken, S. Azoulay, C.B Billing, E.J. Watsky, J. Gong, K.E Williams and K.R Reeves, JAMA, 296, 47 (2006); https://doi.org/10.1001/jama.296.1.47
  46. Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity, March 22 (2022); https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide; Accessed on 5th March 2022.
  47. P.C. Dunnett and G.M. Telling, Int. J. Cosmet. Sci., 6, 241 (1984); https://doi.org/10.1111/j.1467-2494.1984.tb00381.x
  48. A.B. Patel, A.H. Asnani, A.J. Vyas, N.K. Patel, A.I. Patel and A.N. Lumbhani, Asian J. Pharm. Res., 10, 187 (2021); https://doi.org/10.52711/2231-5691.2021.00034
  49. E.S. Carlson, P. Upadhyaya and S.S. Hecht, Chem. Res. Toxicol., 29, 2194 (2016); https://doi.org/10.1021/acs.chemrestox.6b00384
  50. S.Y. Lee and J.B. Guttenpbn, Carcinogenesis, 2, 1339 (1981); https://doi.org/10.1093/carcin/2.12.1339
Read More
Author biographies is not available.
Download
AJC-35-4-2
Statistic
Read Counter : 3 Download : 1